- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Clinical Citations: Obstructive sleep apnea and cardiovascular events: Can CPAP reduce risks?
Severe obstructive sleep apnea- hypopnea syndrome (OSAHS) increases the risk of cardiovascular events in men, according to a large, prospective, controlled study by Marin and associates. Fortunately, this study also demonstrated that treatment with nasal continuous positive airway pressure (CPAP) reduces this risk.
Severe obstructive sleep apnea- hypopnea syndrome (OSAHS) increases the risk of cardiovascular events in men, according to a large, prospective, controlled study by Marin and associates. Fortunately, this study also demonstrated that treatment with nasal continuous positive airway pressure (CPAP) reduces this risk.
The study included 403 men with untreated mild to moderate OSAHS, 235 men with untreated severe OSAHS, 372 men with OSAHS who were treated with nasal CPAP, 377 men who snored but did not have OSAHS, and 264 healthy men. The incidences of fatal and nonfatal cardiovascular events were significantly higher in patients with untreated severe OSAHS than in the other groups.
A multivariate analysis that adjusted for potential confounding variables indicated that untreated severe disease was associated with increased risk of both fatal (odds ratio [OR], 2.87) and nonfatal (OR, 3.17) cardiovascular events.
The authors noted that CPAP may reduce cardiovascular risks in patients with OSAHS by correcting hypertension, nocturnal hypoxemia, endothelial dysfunction, or platelet aggregation abnormalities.
